New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...
The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...
FORT WORTH, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and ...
Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...
LOS ANGELES--(BUSINESS WIRE)--OTITOPIC™ recently announced a new additional indication for treatment of lung cancer for its aspirin inhalation product. Delivering an inhaled Dry Powder formulation of ...
The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension ...
Catalent to collaborate on the scalability and manufacturing for TFF Pharmaceuticals’ proprietary Thin Film Freezing technology Collaboration focused on development of dry powder formulations of ...
Switching from a metered dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...
How to step up asthma treatment in a child who can't use a dry powder inhaler (DPI) licensed for Maintenance and Reliever ...
DUBLIN--(BUSINESS WIRE)--The "Dry Powder Inhaler Devices Device Pipeline Study- Analysis of Devices under Development, Companies, Developments and Outlook" report has been added to ...
Newly published data in the Journal of Drug Delivery Science and Technology demonstrate more uniform drug distribution in the lung compared with other technologies FORT WORTH, Texas, Sept. 26, 2024 ...